Fluidigm
Imaging Mass Cytometry Discovers Tumor Microenvironment Features Predicting Lung Cancer Outcomes
Researchers applied a deep-learning approach to generate a model to predict lung cancer progression based on the tumor microenvironment.
Standard BioTools to Restructure, Discontinue Certain Products as Q2 Revenues Drop 39 Percent
The company's Q2 revenues fell 39 percent, and its net loss more than tripled as it continues to implement a new corporate strategy initiated earlier this year.
Standard BioTools Q1 Revenues Fall 19 Percent
In Q1 the company formerly known as Fluidigm completed a strategic evaluation process and closed a $250 million capital infusion from Casdin Capital and Viking Global Investors.
Companies including Bruker, Akoya, and Standard BioTools either released new platforms or highlighted advances in their systems' capabilities at the meeting.
Fluidigm Appeal in IonPath Patent Infringement Battle Voluntarily Dismissed
The verdict seemingly closes a lawsuit filed by Fluidigm against IonPath in 2019 for allegedly infringing patents covering Fluidigm's mass cytometry technology.